CHMP recommends wider labels for Pfizer's Revatio, Lilly's Alimta and GSK's H5N1 vaccine
This article was originally published in Scrip
The CHMP has recommended broader indications for Pfizer's antihypertensive Revatio (sildenafil), Lilly's antifolate Alimta (pemetrexed disodium) and GlaxoSmithKline's prepandemic H5N1 vaccine Prepandrix, during its May meeting.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.